BLAINJECTIONINJECTABLE2 Generics Approved
Approved
Apr 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
21
Data completeness
5/8 — Partial
LANTUS (insulin glargine) by Sanofi. Approved for insulin analog [epc]. First approved in 2000.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LANTUS (insulin glargine) is a long-acting basal insulin analog administered by subcutaneous injection for the treatment of type 1 and type 2 diabetes mellitus. It provides sustained glucose control by mimicking the body's basal insulin secretion over approximately 24 hours. The drug works through insulin receptor binding to facilitate glucose uptake and utilization in peripheral tissues.
$736MPart D
LOE ApproachingDeclining
As LOE approaches with significant generic/biosimilar competition, commercial teams are consolidating and shifting focus toward newer formulations like LANTUS SOLOSTAR ($3.2B) and next-generation basal insulins.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (21)
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Started Aug 2025
877 enrolled
Diabetes Mellitus, Type 1
Study to Demonstrate Pharmacokinetic and Pharmacodynamic Similarity Between NKF-INS Glargine (G), United States (US)-Lantus®, and European Union (EU)-Lantus®
Started Oct 2024
114 enrolled
Healthy Participants
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
Started Apr 2024
429 enrolled
Diabetes, Type 2
A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)
Started Feb 2024
485 enrolled
Type 2 Diabetes
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
Started Nov 2023
546 enrolled
Type 2 Diabetes
Worked on LANTUS at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.